Investors

Wall Street Stockwatch
Wasatch Pharmaceuticals: Company Update

Special Corporate Update WSCH

Company Name Wasatch Pharmaceuticals (OTCBB: WSCH)

Current Price $0.007

52-Week High $1.95

52-Week Low $0.0045

News from Wasatch Pharmaceutical (OTCBB: WSCH) is hard to come by lately. Gary Heesch, CEO of Wasatch, doesn't buy the idea that a press release every day is productive. He feels "it is usually perceived as an effort to over- promote the stock." But what about the future of WSCH? Why should anyone buy or hold their stock with no news?

Mr. Heesch feels that past news releases and their record of Company accomplishments speak for themselves. For example, Wasatch, now in its 18th year of research, has produced skin care products for the treatment of most common skin disorders. This puts them years ahead of the competition.

In the last 12 months, WSCH has addressed a whole new dimension in preparation for launching its products into the worldwide marketplace, so that millions of people will finally have access to therapies that allow them to remedy their skin disorders and live more normal lives. This preparation involved:

(1) A new management team with impressive individual records of creating billions of dollars in revenue for Oracle, Bausch & Lomb, and Warner Lambert.

(2) The establishment of a new AISC Distribution Center that is fully inventoried with products ready for shipment.

(3) Establishing beautiful corporate offices separate from the company's clinic.

(4) Relocation of the American Institue of Skin Care clinic to a facility designed to be the prototype for future clinics.

To cap off the last 12 months, patents were filed for five new products that will be packaged and ready for release to physicians and hospitals this year. All of these accomplishments translate into a variety of activites and relationships that will insure the growth and stability of WSCH.

When pressed to reveal this year's plans, Mr. Heesch wants to reserve the substance of these activities until they are completed and tucked away. He did say that existing activities and plans include the acquisition of existing medical clinics, ongoing discussion for foreign licensing, conversations with groups of physicians that can represent as many as 2,000 physicians converting their patients to Wasatch products for their skin care problems, and also a possible merger that will expand WSCH's sphere of influence in the medical community.

As these activities come to fruition, they will be disclosed to WSCH shareholders and the public in detail. Unlike many companies struggling with today's economy, Wasatch Pharmaceutical is alive and well and working towards a productive future.

Stay tuned for plenty more to come from WSCH.

To be removed from future mailings, please respond
to this email with "Remove" in the subject line

DISCLAIMER:
Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements."

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "projects", "foresee", "expects", "will," "anticipates," "estimates," "believes," "understands" or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks, securities must be understood as information provided and not investment advice. Emerging Growth Stock Alert advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice.

In compliance with the Securities Act of 1933, Section17(b), Emerging Growth Stock Alert discloses the receipt of ten million unrestricted shares of WSCH from a third party for the publication of this report and additional services related to WSCH. Be aware of an inherent conflict of interest resulting from such compensation due to our intent to profit from the sale of these shares. All factual information in this report was gathered from public sources, including but not limited to SEC filings, Company Press Releases, and the company's website at wasatchpharm.com. Emerging Growth Stock Alert believes this information to be reliable but can make no guarantee as to its accuracy or completeness. Use of the material within this email constitutes your acceptance of these terms.

To be removed from future mailings, please respond
to this email with "Remove" in the subject line